Drugs / KQB198
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06720987 | Feb 2025 → Jun 2029 expected | colorectal cancer | Kumquat Biosciences Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06645886 | Dec 2024 → Mar 2027 expected | hematopoietic and lymphoid cell neoplasm | Kumquat Biosciences Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06507306 | Jun 2024 → Jul 2026 overdue | cancer | Kumquat Biosciences Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07406633 | Jun 2026 → Oct 2027 expected | gastrointestinal stromal tumor | Kumquat Biosciences Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KQB198 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06645886 ↗ |
| Route | Oral | “Oral KQB198” NCT06507306 ↗ |